abstract |
This invention provides novel, substantially uncleavable forms of gp 160, and vaccine formulations containing gp 160 or a derivative thereof, adjuvanted with 3-D Mpl. The compositions are useful for the immunotherapeutic and immunoprophylatic treatment of HIV infections. |